297 related articles for article (PubMed ID: 11038071)
1. Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy.
Anderson JE; Weber M; Vargas C
Cell Transplant; 2000; 9(4):551-64. PubMed ID: 11038071
[TBL] [Abstract][Full Text] [Related]
2. Correlated NOS-Imu and myf5 expression by satellite cells in mdx mouse muscle regeneration during NOS manipulation and deflazacort treatment.
Anderson JE; Vargas C
Neuromuscul Disord; 2003 Jun; 13(5):388-96. PubMed ID: 12798794
[TBL] [Abstract][Full Text] [Related]
3. Deflazacort but not prednisone improves both muscle repair and fiber growth in diaphragm and limb muscle in vivo in the mdx dystrophic mouse.
Anderson JE; McIntosh LM; Poettcker R
Muscle Nerve; 1996 Dec; 19(12):1576-85. PubMed ID: 8941272
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of deflazacort and doxycycline: a potential pharmacotherapy for Duchenne muscular dystrophy.
Pereira JA; Marques MJ; Santo Neto H
Clin Exp Pharmacol Physiol; 2015 Jul; 42(7):788-94. PubMed ID: 25959722
[TBL] [Abstract][Full Text] [Related]
5. Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy.
Wuebbles RD; Sarathy A; Kornegay JN; Burkin DJ
Dis Model Mech; 2013 Sep; 6(5):1175-84. PubMed ID: 23846963
[TBL] [Abstract][Full Text] [Related]
6. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort.
Archer JD; Vargas CC; Anderson JE
FASEB J; 2006 Apr; 20(6):738-40. PubMed ID: 16464957
[TBL] [Abstract][Full Text] [Related]
7. Nuclear magnetic resonance spectroscopy study of muscle growth, mdx dystrophy and glucocorticoid treatments: correlation with repair.
McIntosh L; Granberg KE; Brière KM; Anderson JE
NMR Biomed; 1998 Feb; 11(1):1-10. PubMed ID: 9608583
[TBL] [Abstract][Full Text] [Related]
8. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.
Burkin DJ; Wallace GQ; Nicol KJ; Kaufman DJ; Kaufman SJ
J Cell Biol; 2001 Mar; 152(6):1207-18. PubMed ID: 11257121
[TBL] [Abstract][Full Text] [Related]
9. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Therapy With Omega-3 Ameliorates Myonecrosis and Benefits Skeletal Muscle Regeneration in Mdx Mice.
Apolinário LM; De Carvalho SC; Santo Neto H; Marques MJ
Anat Rec (Hoboken); 2015 Sep; 298(9):1589-96. PubMed ID: 26011009
[TBL] [Abstract][Full Text] [Related]
11. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
[TBL] [Abstract][Full Text] [Related]
12. Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy.
Skrabek RQ; Anderson JE
Muscle Nerve; 2001 Feb; 24(2):192-202. PubMed ID: 11180202
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy.
Dubinin MV; Talanov EY; Tenkov KS; Starinets VS; Belosludtseva NV; Belosludtsev KN
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228255
[TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with deflazacort decreases myocardial fibrosis in mdx mice.
Marques MJ; Oggiam DS; Barbin IC; Ferretti R; Santo Neto H
Muscle Nerve; 2009 Sep; 40(3):466-8. PubMed ID: 19623634
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway.
St-Pierre SJ; Chakkalakal JV; Kolodziejczyk SM; Knudson JC; Jasmin BJ; Megeney LA
FASEB J; 2004 Dec; 18(15):1937-9. PubMed ID: 15456738
[TBL] [Abstract][Full Text] [Related]
16. Deflazacort treatment of Duchenne muscular dystrophy.
Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA
J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511
[TBL] [Abstract][Full Text] [Related]
17. Regeneration and myogenic cell proliferation correlate with taurine levels in dystrophin- and MyoD-deficient muscles.
McIntosh LM; Garrett KL; Megeney L; Rudnicki MA; Anderson JE
Anat Rec; 1998 Oct; 252(2):311-24. PubMed ID: 9776086
[TBL] [Abstract][Full Text] [Related]
18. The effects of altered metabolism (hypothyroidism) on muscle repair in the mdx dystrophic mouse.
McIntosh LM; Pernitsky AN; Anderson JE
Muscle Nerve; 1994 Apr; 17(4):444-53. PubMed ID: 8170492
[TBL] [Abstract][Full Text] [Related]
19. Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment.
Butchart LC; Terrill JR; Rossetti G; White R; Filipovska A; Grounds MD
Int J Biochem Cell Biol; 2018 Jun; 99():52-63. PubMed ID: 29578051
[TBL] [Abstract][Full Text] [Related]
20. Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice.
Fogagnolo Mauricio A; Minatel E; Santo Neto H; Marques MJ
Clin Nutr; 2013 Aug; 32(4):636-42. PubMed ID: 23218947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
